Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis ...

Though there are very few characters in MASH who aren't beloved by audiences and critics, these individuals rise to the top ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared with ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Because nothing tests your patience — or your posture — like youth sports season. NEW YORK , NY May 6, 2025 With Mother's Day ...

Target RWE, a leader in modern clinical evidence generation for complex diseases, today announced its presentations and strategic contributions at the EASL Congress 2025 in Amsterdam, Netherlands.

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

This local sensation mashes up pop and rock hits with a full brass section, turning every show into a high-energy singalong.